LR Health & Beauty SE Reports Mixed First Half of 2026

LR Health & Beauty SE announced a decrease in sales for H1 2026, reaching EUR 118.6 million, down from EUR 142.9 million in the previous year. The company's reported EBITDA also declined to EUR 3.9 million, influenced by a challenging market and restructuring costs.

Despite the setbacks, the company continues its strategic initiatives, focusing on sustainable organizational development and future growth. Important measures include investments at its Ahlen production site and optimizing logistics and international expansion.

CEO Jörg Körfer emphasized the completed financial realignment and upcoming September Business Days as key to deepening community engagement and boosting activities.

Efforts in digitalization and automation also aim to enhance LR's flexibility and scalability in the coming years.